MedTrace Logo

A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer

NCT01165021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-09-25

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed

500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles

DRUG

Cisplatin

75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles

DRUG

Folic Acid

Administered orally.

DRUG

Vitamin B12

Administered Intramuscular injection.

DRUG

Dexamethasone

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-07-31
Completion
2016-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165021 on ClinicalTrials.gov